Graybug Vision IncNASDAQ:GRAYNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7237
- TODAY'S CHANGE (%)-0.0263 (-3.5067%)
- Bid / Lots0.6800/ 6
- Ask / Lots0.7400/ 15
- Open / Previous Close0.7500 / 0.7500
- Day Range
- 52 Week Range
- Volume20,122
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRAY |
|---|---|---|
| 09:32 ET | 100 | 0.75 |
| 09:57 ET | 100 | 0.73 |
| 10:27 ET | 100 | 0.72 |
| 11:30 ET | 201 | 0.75 |
| 01:24 ET | 2000 | 0.7201 |
| 01:26 ET | 2799 | 0.725 |
| 01:27 ET | 2000 | 0.725 |
| 01:29 ET | 1800 | 0.72 |
| 01:40 ET | 1000 | 0.707101 |
| 01:49 ET | 600 | 0.7173 |
| 01:51 ET | 551 | 0.7275 |
| 02:03 ET | 900 | 0.7071 |
| 02:12 ET | 375 | 0.7096 |
| 02:21 ET | 5000 | 0.69545 |
| 02:23 ET | 388 | 0.6847 |
| 02:27 ET | 1200 | 0.6847 |
| 02:36 ET | 300 | 0.6882 |
| 03:15 ET | 200 | 0.7237 |
Dec 29, 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BNFT, LBC, ELVT, GRAY, from 9:32AM ET on Thursday Dec 29, 2022 by GlobeNewswire
9:32AM ET on Thursday Dec 29, 2022 by GlobeNewswire
Dec 28, 2022
BRIEF-Graybug Vision Receives Notice Of Delisting From Nasdaq, from 4:06PM ET on Wednesday Dec 28, 2022 by Thomson Reuters
4:06PM ET on Wednesday Dec 28, 2022 by Thomson ReutersSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - IMRA, SAL, APEN, GRAY, from 3:41PM ET on Wednesday Dec 28, 2022 by GlobeNewswire
3:41PM ET on Wednesday Dec 28, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Graybug Vision Inc | 16.2M | -0.4x | --- |
Galmed Pharmaceuticals Ltd | 16.1M | -0.7x | --- |
CeCors Inc | 15.8M | 0.0x | --- |
Neurobo Pharmaceuticals Inc | 15.6M | -0.1x | --- |
NanoViricides Inc | 16.8M | -2.4x | --- |
Bio Path Holdings Inc | 17.3M | -1.1x | --- |
Company Information
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The Company's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The Company is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Contact Information
- Headquarters
- 203 Redwood Shores Parkway, Suite 620REDWOOD CITY, CA, United States 94065
- Phone
- 650-487-2800
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Christy Shaffer
- President, Chief Executive Officer, Director
- Frederic Guerard
- Chief Financial Officer
- Robert Breuil
- Chief Medical Officer
- Parisa Zamiri
- Independent Director
- Christina Ackermann
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.72 |
Book Value | $3.04 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
